- Home
- CRNX vs NAD Comparison
CRNX vs NAD Comparison
Compare CRNX & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- NAD
- Stock Information
- Founded
- CRNX 2008
- NAD 1999
- Country
- CRNX United States
- NAD United States
- Employees
- CRNX N/A
- NAD N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- NAD Investment Managers
- Sector
- CRNX Health Care
- NAD Finance
- Exchange
- CRNX Nasdaq
- NAD Nasdaq
- Market Cap
- CRNX 2.8B
- NAD 2.6B
- IPO Year
- CRNX 2018
- NAD N/A
- Fundamental
- Price
- CRNX $30.16
- NAD $11.15
- Analyst Decision
- CRNX Strong Buy
- NAD
- Analyst Count
- CRNX 10
- NAD 0
- Target Price
- CRNX $75.00
- NAD N/A
- AVG Volume (30 Days)
- CRNX 676.7K
- NAD 595.7K
- Earning Date
- CRNX 08-07-2025
- NAD 01-01-0001
- Dividend Yield
- CRNX N/A
- NAD 4.35%
- EPS Growth
- CRNX N/A
- NAD N/A
- EPS
- CRNX N/A
- NAD N/A
- Revenue
- CRNX $760,000.00
- NAD N/A
- Revenue This Year
- CRNX $402.12
- NAD N/A
- Revenue Next Year
- CRNX $770.88
- NAD N/A
- P/E Ratio
- CRNX N/A
- NAD N/A
- Revenue Growth
- CRNX N/A
- NAD N/A
- 52 Week Low
- CRNX $24.10
- NAD $9.56
- 52 Week High
- CRNX $62.53
- NAD $11.64
- Technical
- Relative Strength Index (RSI)
- CRNX 41.11
- NAD 44.03
- Support Level
- CRNX $32.05
- NAD $11.13
- Resistance Level
- CRNX $31.56
- NAD $11.25
- Average True Range (ATR)
- CRNX 1.08
- NAD 0.08
- MACD
- CRNX -0.18
- NAD -0.00
- Stochastic Oscillator
- CRNX 5.25
- NAD 10.87
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.